Halozyme Therapeutics, Inc. (NASDAQ: HALO) disclosed that its President and Chief Executive Officer, Helen Torley, sold common stock valued at approximately $6.0 million in a series of transactions last week. The sales took place between November 12 and November 16, 2026, according to the report.
Torley disposed of 60,000 shares at prices spanning $96.440 to $101.940 per share. The sales were executed pursuant to a pre-arranged trading plan adopted on December 3, 2025, under Rule 10b5-1. The shares sold were acquired following the exercise of stock options with ten-year terms expiring in February 2028 and February 2029.
In conjunction with the sales, Torley exercised options to acquire 60,000 shares of Halozyme common stock. These acquisitions totaled approximately $1.04 million, with exercise prices ranging from $16.65 to $18.41 per share. The options were part of grants made to Torley in February 2018 and February 2019.
After the reported transactions, Torley directly beneficially owns 767,780 shares of Halozyme common stock.
The insider activity follows Halozyme's third-quarter 2026 financial results, which surpassed Wall Street expectations. The company reported adjusted earnings of $2.39 per share on revenue of $492.97 million, compared to estimates of $2.28 per share and $487.13 million in revenue. Halozyme also raised its full-year guidance across several key measures.
Despite the positive earnings, the stock declined, reflecting investor concerns over valuation, litigation, and the pace of future growth. Additionally, Morgan Stanley downgraded Halozyme's stock rating to Equalweight from Overweight, citing a diversified royalty base and strengthened European intellectual property position. The firm adjusted its price target to $109, reflecting the current royalty portfolio, which is expected to peak in 2029. Meanwhile, TD Cowen reiterated a Buy rating on Halozyme, maintaining a price target of $130, and noted the recent stock pullback as a buying opportunity.
The sale by the CEO comes amid this mixed analyst sentiment and may draw attention from investors monitoring insider transactions for signals about management's confidence and valuation perceptions.